Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | plasmepsin VI | 0.0373 | 0.1578 | 0.2693 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0373 | 0.1578 | 0.2693 |
Plasmodium falciparum | plasmepsin I | 0.0373 | 0.1578 | 0.2693 |
Plasmodium vivax | plasmepsin IV, putative | 0.0373 | 0.1578 | 0.2693 |
Plasmodium falciparum | plasmepsin IV | 0.0373 | 0.1578 | 0.2693 |
Echinococcus granulosus | cathepsin d lysosomal aspartyl protease | 0.0373 | 0.1578 | 0.5 |
Plasmodium falciparum | plasmepsin V | 0.0757 | 0.5862 | 1 |
Toxoplasma gondii | aspartyl protease ASP5 | 0.0606 | 0.418 | 1 |
Loa Loa (eye worm) | aspartic protease BmAsp-2 | 0.0373 | 0.1578 | 0.5 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.1128 | 1 | 1 |
Toxoplasma gondii | aspartyl proteinase (eimepsin), putative | 0.0373 | 0.1578 | 0.3776 |
Plasmodium vivax | plasmepsin V, putative | 0.0757 | 0.5862 | 1 |
Echinococcus multilocularis | cathepsin d (lysosomal aspartyl protease) | 0.0373 | 0.1578 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0373 | 0.1578 | 0.5 |
Trichomonas vaginalis | Clan AA, family A1, cathepsin D-like aspartic peptidase | 0.0373 | 0.1578 | 0.5 |
Toxoplasma gondii | aspartyl protease ASP1 | 0.0373 | 0.1578 | 0.3776 |
Plasmodium falciparum | plasmepsin II | 0.0373 | 0.1578 | 0.2693 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 38 % | Antiparasitic activity against Trichomonas vaginalis T1 at 100 uM after 24 hrs by hemocytometric analysis | ChEMBL. | 20667728 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.